Clinical study on ibandronate combined with chemotherapy in treatment of lung cancer with bone metastasis / 中国癌症杂志

ABSTRACT

Background and purpose:The skeleton is the most common site of tumor metastasis in lung cancer.Skeletal complications from bone metastasis,such as severe bone pain,functional impairment,may substantially reduce quality of life,in some situations,may result in death.We explored the efficacy of ibandronate combined with chemotherapy in treatment of lung cancer with bone metastasis.Methods:Sixty-four lung cancer patients with bone metastasis were randomized into two groups:38 patients in study group received normal chemotherapy combined with ibandronate,and 26 patients in control group received normal chemotherapy only.Results:The response rate of pain relief in the study group and control group was 71.1% and 42.3%,respectively(P=0.006).In study group,serum alkaline phosphatise and serum calcium was decreased after treatment by ibandronate combined with chemotherapy(P0.05).Conclusion:Ibandronate is safe and well tolerated. Ibandronate combined with chemotherapy is effective in relief of the pain caused by bone metastases and may inhibit bone metastasis.